These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18217998)

  • 1. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
    Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
    HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lipid profile of atazanavir].
    Martínez Chamorro E
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():34-40. PubMed ID: 20116615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
    Grover SA; Coupal L; Gilmore N; Mukherjee J
    Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
    Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
    AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
    Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
    AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case presentation: nephrolithiasis in a patient treated with atazanavir.
    Savini C; James C; Wilson S; Martin H; Szabo S; Scotto V
    J Assoc Nurses AIDS Care; 2008; 19(3):225-7. PubMed ID: 18457764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences.
    Neumann T; Woiwod T; Neumann A; Ross B; Von Birgelen C; Volbracht L; Brockmeyer NH; Gerken G; Erbel R
    Eur J Med Res; 2004 Feb; 9(2):55-60. PubMed ID: 15090290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.
    de Saint-Martin L; Bressollette L; Perfezou P; Bellein V; Ansart S; Vallet S; Pasquier E
    AIDS; 2010 Nov; 24(18):2797-801. PubMed ID: 21063175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
    Murphy RL; Berzins B; Zala C; Fichtenbaum C; Dube MP; Guaraldi G; Torriani F; Belsey E; Mitchell C; Stein JH;
    AIDS; 2010 Mar; 24(6):885-90. PubMed ID: 19952712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult.
    Jacques AC; Giguère P; Zhang G; Touchie C; la Porte CJ
    Ann Pharmacother; 2010 Jan; 44(1):202-6. PubMed ID: 19955297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atazanavir urolithiasis.
    Chang HR; Pella PM
    N Engl J Med; 2006 Nov; 355(20):2158-9. PubMed ID: 17108352
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial.
    Flammer AJ; Vo NT; Ledergerber B; Hermann F; Gämperli A; Huttner A; Evison J; Baumgartner I; Cavassini M; Hayoz D; Quitzau K; Hersberger M; Sudano I; Ruschitzka F; Lüscher TF; Noll G; Weber R
    Heart; 2009 Mar; 95(5):385-90. PubMed ID: 18653575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does atazanavir cause lipodystrophy?
    Gazzard BG; Moyle G
    J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects.
    Guffanti M; Caumo A; Galli L; Bigoloni A; Galli A; Dagba G; Danise A; Luzi L; Lazzarin A; Castagna A
    Eur J Endocrinol; 2007 Apr; 156(4):503-9. PubMed ID: 17389467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
    Iloeje UH; Yuan Y; L'italien G; Mauskopf J; Holmberg SD; Moorman AC; Wood KC; Moore RD
    HIV Med; 2005 Jan; 6(1):37-44. PubMed ID: 15670251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.